The cancer vaccines need to trigger CD8+ T cell activation and anti-cancer CTL responses from major histocompatibility complex (MHC) class I antigen presentation of tumor antigens by antigen presentation cells (APCs) such as dendritic cells (DCs) and macrophages. This evidence concerns the gene CD8A and cancer.